ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Bayer to acquire KaNDy Therapeutics

by Ryan Cross
August 13, 2020 | APPEARED IN VOLUME 98, ISSUE 31

 

Bayer is paying $425 million for KaNDy Therapeutics, a UK firm developing a small-molecule treatment to reduce hot flashes from menopause. Bayer touts the investment as its latest move in women’s health, after signing a license for Daré Bioscience’s experimental monthly contraceptive and forming a gynecological disease research pact with Dewpoint Therapeutics. KaNDy’s lead compound, NT-814, inhibits neurokinin-1 and neurokinin-3 receptors, which are involved in regulating body heat. KaNDy could earn up to $450 million in milestone payments from Bayer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment